FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models

The FDA's July 2026 guidance broadens cancer clinical trial eligibility by recommending inclusion of patients with ECOG performance status 2 unless justified otherwise, challenging traditional enrollment models and imposing new operational requirements for trial sites.

This Wire brief sits within Fusion42's coverage of Health.